Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790073 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study With SNF472 in Calciphylaxis Patients
A Phase 2 study, sponsored by Sanifit Therapeutics S. A..
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02790073 is a Phase 2 study that has completed, run by Sanifit Therapeutics S. A.. The registered enrollment target is 14 participants.
The verdict
NCT02790073, a Phase 2 study, has completed, sponsored by Sanifit Therapeutics S. A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
Interventions
- DRUG SNF472
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02790073
The ClinicalTrials.gov registry entry for NCT02790073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanifit Therapeutics S. A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNF472 is the first listed.
NCT02790073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02790073 about?
NCT02790073 is a clinical study titled "Phase 2 Study With SNF472 in Calciphylaxis Patients". To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
What is the current status of trial NCT02790073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-05. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT02790073?
The interventions under investigation include: SNF472 (DRUG).
Who is sponsoring clinical trial NCT02790073?
This trial is sponsored by Sanifit Therapeutics S. A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.